GlassScriptPhysician profile
Michael Gary Lapinski
NPI 1902505639
$1,405.39
in general payments reported to CMS, 2019-2025
11 companies · $724 in 2025
The $724 reported for 2025 was more than what a typical Psychiatric/Mental Health (Nurse Practitioner) provider received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $40.44 · 2024: $641 · 2025: $724.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,405.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,405.39 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neuronetics, INC. | $582.26 | 2023-2024 | Neurostar Tms Therapy System |
| Abbvie INC. | $199.42 | 2025 | |
| Otsuka America Pharmaceutical, INC. | $148.04 | 2025 | Rexulti |
| Axsome Therapeutics, INC. | $119.32 | 2024-2025 | Auvelity |
| Alkermes, INC. | $103.87 | 2025 | Aristada, Lybalvi, Vivitrol |
| Neurocrine Biosciences, INC. | $71.40 | 2025 | |
| Janssen Pharmaceuticals, INC | $69.28 | 2023-2025 | Spravato, Invega Sustenna |
| Vanda Pharmaceuticals INC. | $44.40 | 2025 | Fanapt |
| Teva Pharmaceuticals USA, INC. | $25.73 | 2025 | Uzedy |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $25.26 | 2025 | Caplyta |
| Smith+Nephew, INC. | $16.41 | 2024 | Collagenase Santyl |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Lapinski listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.